Bradykinesia News and Research

RSS

Aerobic exercise combined with tDCS improves the gait of Parkinson's patients

Transcranial direct current stimulation (tDCS) can increase the benefits of aerobic exercise and improve the gait of patients with Parkinson's disease immediately after a session. Step time variability decreases, reaction time shortens, and executive control of gait is enhanced.

25 Aug 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

Pioneering neural recordings lay the groundwork for personalized Parkinson's treatments

Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.

4 May 2021

Researchers survey patients to find out which Parkinson's symptoms troubled the most

Individuals with Parkinson's disease (PD) face a wide range of symptoms and challenges. A team from Parkinson's UK, including several Patient and Public Involvement (PPI) contributors, surveyed patients to find out which PD symptoms troubled them most and how priorities may change with condition duration.

27 Apr 2021

Anti-diabetic drug could be repurposed for treating Parkinson's disease

A hallmark of Parkinson's disease is the degeneration of a group of dopaminergic neurons in the brain, which play key roles in movement initiation and co-ordination.

24 Nov 2020

Parkinson's disease breakthrough seen in mouse model

Researchers from the University of California San Diego School of Medicine have found a way to create new neurons in a mouse model of Parkinson's disease. The severely debilitating and progressive neurodegenerative disease, as of now, has no cure, and this breakthrough could help hundreds of thousands of patients with the condition feel experts.

25 Jun 2020

Genetic engineering could open possibilities for patients with Parkinson’s disease

People with Parkinson’s disease experience loss of dopamine-producing brain cells, leading to tremors, rigidity, bradykinesia, and postural instability, the primary symptoms of the disease.

11 Sep 2019

"Smart" deep brain stimulators for Parkinson’s

A new study from the scientists at the University of Houston reveals specific neuromarkers for Parkinson’s disease. Deep brain stimulation for Parkinson’s disease could now be targeted towards cells carrying these markers in the brain and thus become more accurate and specific explain the researchers.

30 Jul 2019

The Opal: Pushing the Boundaries of Parkinson’s Disease Research

An interview with Dr. Kristen Sowalsky, discussing a wearable gait sensor and its impact on Parkinson’s disease research.

From APDM Wearable Technologies 8 Jan 2019

Newly discovered compound shows potential for treating Parkinson's disease

A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.

19 Oct 2018

Reprogrammed stem cell therapy shows promise in Parkinson's

Japanese investigators have found that their experimental stem cell therapy for Parkinson’s disease actually works. In their experimental therapy, the team of researchers “reprogrammed” stem cells to make them neurons and implanted them into the brain of monkeys with a version of Parkinson’s disease. Stem cell therapy showed improvement of symptoms in these patients and was found to be safe. The study was published yesterday, 30th August 2017 in Nature.

30 Aug 2017

Smartphone-based biofeedback rehabilitation system aims to improve balance in Parkinson's patients

University of Houston researchers in the Department of Health and Human Performance are helping patients with Parkinson's disease regain stable balance and confidence in performing daily activities in their own homes.

31 Jul 2017

Physical activity may help improve health and quality of life of Parkinson's disease patients

A comprehensive review published in the Journal of Parkinson's Disease confirms that people living with Parkinson's disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls.

15 Nov 2016

FAU's clinical trial to evaluate efficacy of RVT-101 tablet for Lewy body dementia

Florida Atlantic University's Charles E. Schmidt College of Medicine is spearheading the South Florida site for the first U.S. clinical trial for Lewy body dementia (LBD), the second-most common dementia after Alzheimer's disease. The HEADWAY-DLB is a phase 2b multi-center, double-blind, placebo-controlled study to evaluate an investigational medicine, RVT-101, for dementia with Lewy bodies.

22 Apr 2016

Lewy Body Composite Risk Score detects LBD and Parkinson's disease dementia in three minutes

Although Lewy Body disease (LBD) is the second-most-common degenerative disease after Alzheimer's disease, it's not exactly a household name. It affects more than 1.3 million Americans, is poorly recognized, and diagnosis is often significantly delayed. Patients with LBD simultaneously experience losses in cognitive function, mobility and behavior.

27 Oct 2015

Dopamine transmission mediated by D1 receptors essential for controlling movements in Parkinson's disease

Dopamine deficiency in the basal ganglia (a set of subcortical structures) causes severe motor dysfunctions, such as slowness of movements (bradykinesia), as observed in Parkinson's disease. Dopamine binds D1 and D2 receptors that are expressed in the nerve cells of the striatum (a structure of the basal ganglia), and exerts different effects on the nerve cells. However, how dopamine controls through these receptors the information flow in the basal ganglia and voluntary movements is still not clear.

6 Oct 2015

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).

30 Jun 2015